Sunshine Biopharma, Inc - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - August 19, 2020

Attached files

file filename
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Sunshine Biopharma, Incsbfm_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Sunshine Biopharma, Incsbfm_ex311.htm
10-Q - QUARTERLY REPORT - Sunshine Biopharma, Incsbfm_10q.htm
 
Exhibit 32
 
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the six month period ended June 30, 2020, as filed with the Securities and Exchange Commission on August 18, 2020 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1. 
The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: August 18, 2020
s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty, Chief Executive Officer
 
 
Dated: August 18, 2020
s/ Camille Sebaaly
Camille Sebaaly, Chief Financial Officer
 
 

Sunshine Biopharma, Inc Reports